APA (7th ed.) Citation

K, S., T, P., KY, S., J, S., M, L., C, R., . . . JH, L. (2024). Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial. JAMA oncology, 10(12), 1663. https://doi.org/10.1001/jamaoncol.2024.4019

Chicago Style (17th ed.) Citation

K, Sehgal, et al. "Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial." JAMA Oncology 10, no. 12 (2024): 1663. https://doi.org/10.1001/jamaoncol.2024.4019.

MLA (9th ed.) Citation

K, Sehgal, et al. "Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial." JAMA Oncology, vol. 10, no. 12, 2024, p. 1663, https://doi.org/10.1001/jamaoncol.2024.4019.